



Patented
Medicine Prices
Review Board

Conseil d'examen du
prix des médicaments
brevetés

October
7 & 8, 2002

Fairmont Château
Laurier, Ottawa,
Ontario

A forum to share
information,
ideas and
views on current
issues in drug
price regulation
in Canada

PmPrB Symposium 2002

Current Issues in Pharmaceutical Price Regulation in Canada

This symposium will be conducted in English and French and simultaneous translation will be available.

Program

As the proportion of health care spending devoted to pharmaceuticals continues to increase, Canadians have more questions about drug prices. Approaches to drug price and cost controls in Canada, and other countries, are continually evolving; many countries are referring to international drug price comparisons. Some countries are placing greater reliance on cost-effectiveness analysis to assist in the decisions on coverage of new drugs. The promise of major breakthroughs in drug therapy offers Canadians great hope, while the potential cost of such treatments is a cause for concern for many individuals and governments.

This is the Program for the two-day PMPRB Symposium 2002. We hope that you will join us for exciting and timely discussions on Current Issues in Pharmaceutical Price Regulation in Canada.

Robert G. Elgie,
Chairperson

Canada

Since 1987
Depuis

Monday, October 7, 2002

8:00 a.m. – 8:45 a.m.

Continental Breakfast for all participants

8:45 a.m. – 8:50 a.m.

Introductory Remarks

- Wayne D. Critchley, Chair of the Symposium

8:50 a.m. – 9:15 a.m.

Welcoming Remarks: How the Patented
Medicine Prices Review Board Contributes to
Controlling Drug Prices in Canada

A presentation on the role of the PMPRB and how it has
evolved since 1987, the PMPRB's Research Agenda and
consultations on the Price Guidelines.

- Robert G. Elgie, Chairperson, PMPRB

9:15 a.m. – 10:00 a.m.

Health Care Expenditures – Current Trends

The CIHI Annual Report 2002 shows that drugs
continue to represent the fastest-growing component
of health care expenditures.

A presentation on the current trends, in Canada and
other countries, in expenditures on health care and
pharmaceuticals.

- Michael Decter, Chairman, Canadian Institute for
Health Information

10:00 a.m. – 10:30 a.m.

Refreshment Break

Advisory Group

D. Bougher

Alberta Health

J.-F. Bussières

Hôpital Ste-Justine

V. Chiles

Green Shield

M. Elston

Rx&D

J. Glennie

Health Canada

E. Hubbard

Nova Scotia

Pharmacare

J. Jones

CAC

J. Keon

CDMA

J. LeLorier

CHUM

J. Lexchin

Toronto Hospital

J. Lomas

CHSRF

D. Menon

Institute of Health

Economics

I. Shugart

Health Canada

M.-J. Thivierge

Industry Canada

10:30 a.m. – 12:15 p.m.

Approaches to Drug Price Regulation in Other Countries

All developed countries debate the merits of controlling drug prices and expenditures and, with the exception of the United States, all have used a variety of measures to do so.

Two speakers who have studied approaches to drug price regulation in developed countries will be asked to speak for no more than 40 minutes each, to be followed by a facilitated discussion and questions and answers from the floor.

- Moderator:
Réal Sureau, Vice-Chairperson, PMPRB
- Speakers:
 - Stéphane Jacobzone, Social Policy Division, OECD
 - Panos Kanavos, International Health Policy, London School of Economics and Political Science, UK

12:15 p.m. – 2:00 p.m.

Keynote Luncheon Address

Canadians and Their Views on Health Care

- Robert Y. McMurtry, Commission on the Future of Health Care in Canada

2:00 p.m. – 3:00 p.m.

Assessing the Value of New Drugs: The UK Experience

A presentation on the current approaches to, and use of, cost-effectiveness and the role of the NICE.

- Professor Sir Michael Rawlins, Chairman, National Institute for Clinical Excellence, UK

3:00 p.m. – 3:30 p.m.

Refreshment Break

3:30 p.m. – 4:30 p.m.

Assessing the Value of New Drugs: The Experience “Down Under”

A presentation on the evolution of approaches to assessing the value of new drugs for reimbursement purposes in Australia.

- Lloyd Sansom, Chairman, Pharmaceutical Benefits Advisory Committee, Australia

4:30 p.m. – 5:00 p.m.

International R&D Comparison Study

A presentation on the results of a study by the PMPRB comparing trends in pharmaceutical R&D spending in Canada and selected countries.

- Ronald J. Corvari, Director, Policy & Economic Analysis, PMPRB

5:30 p.m. – 7:00 p.m.

Greetings from the Minister of Health,
the Honourable Anne McLellan, P.C., M.P.

Reception and Cash Bar

Tuesday, October 8, 2002

8:00 a.m. – 9:00 a.m.

Continental Breakfast

9:00 a.m. – 10:30 a.m.

Assessing the Value of New Drugs: Where is Canada Heading?

A panel discussion on the future of pharmacoeconomics in Canada with the participation of representatives of federal/provincial/territorial health ministries, the pharmaceutical industry and others.

In 1992, a number of organizations endorsed national guidelines for pharmacoeconomic studies which have subsequently been housed by the Canadian Coordinating Office for Health Technology Assessment (CCOHTA). Several provinces require manufacturers to include pharmacoeconomic studies as part of their submissions for formulary listing.

- What has been the experience with pharmacoeconomics to date in Canada? How are studies used?
- Will pharmacoeconomics come to occupy a greater role in the listing decisions of public drug plans?
- How do private insurers use cost-effectiveness analysis?
- What lessons can we learn from other countries?

Each panellist will be asked to speak for no more than 10 minutes, to be followed by a facilitated discussion and questions and answers from the floor.

- Moderator:
 - Anthony Boardman, Member, PMPRB;
Faculty of Commerce and Business
Administration, University of British Columbia

- Panellists:
 - Vernon Chiles, Vice-Chair, Green Shield Canada
 - Eleanor Hubbard, Director, Pharmaceutical Services, Nova Scotia; Chair, CCOHTA
 - Andreas Laupacis, President, Institute for Clinical Evaluative Sciences
 - Terry McCool, Vice President, Corporate Affairs, Eli Lilly Canada Inc.

10:30 a.m. – 11:00 a.m.

Refreshment Break

11:00 a.m. – 12:30 p.m.

International Experience with Pharmaceutical Industrial Policy: Common Challenges and Lessons for Canada

A presentation on issues related to public policies to balance and encourage pharmaceutical R&D investment and consumer protection in access to medicines at reasonable prices.

- Don Willison, Centre for Evaluation of Medicines, McMaster University

This presentation will be followed by a panel discussion. Each panellist will be asked to speak for no more than 10 minutes, to be followed by a facilitated discussion and questions and answers from the floor.

- Moderator:
 - Linda Tennant, former Director, Ontario Drug Benefit Plan
- Panellists:
 - Murray Elston, President, Canada's Research Based Companies (Rx&D)
 - Jim Keon, President, Canadian Drug Manufacturers' Association (CDMA)
 - Jacques LeLorier, Research Centre, *Centre hospitalier de l'Université de Montréal*, Hôtel-Dieu Pavillon
 - Don Willison

12:30 p.m. – 1:30 p.m.

Luncheon

1:30 p.m. – 3:00 p.m.

The National Prescription Drug Utilization Information System (NPDUIS): How Can it Be Used to Promote Optimal Drug Therapy?

In September 2001, the Federal/Provincial/Territorial Ministers of Health announced a multi-faceted approach to better pharmaceuticals management. Among other things, they agreed to establish the NPDUIS, as a partnership between the PMPRB and the Canadian Institute for Health Information (CIHI).

- What opportunities and challenges are presented by the establishment of the NPDUIS?
- What are some of the policy questions it should try to address?
- How can the system be used to promote optimal drug utilization in Canada?

Each panellist will be asked to speak for no more than 10 minutes, to be followed by a facilitated discussion and questions and answers from the floor.

- Moderator:
 - Ingrid Sketris, Member, PMPRB;
College of Pharmacy, Dalhousie University
- Panellists:
 - Stuart MacLeod, Director, Father Sean O’Sullivan Research Centre; Faculty of Health Sciences, McMaster University
 - Jeffrey Poston, Executive Director
Canadian Pharmacists Association
 - Barb Shea, Executive Director,
Drug Plan and Extended Benefits,
Saskatchewan Health
 - Ian Shugart, Assistant Deputy Minister,
Health Policy & Communications, Health Canada

3:00 p.m. – 3:30 p.m.

Refreshment Break

3:30 p.m. – 5:00 p.m.

The Future of Pharmacotherapy

Genetic research is opening the possibility of new approaches to pharmaceutical development and treatment. What issues will be raised by new technologies in assessing the value of new drugs?

Our panel will be asked to share their thoughts on the questions many are asking about the changing landscape in drug development and technology.

- What pharmaceutical innovations can be expected in the next decade? Will we see more “designer drugs” - drugs developed to target specific genetic traits?
- What are the challenges for drug development? What will drive pharmaceutical R&D? With genetic technology, will drug development become more or less costly?
- Will the new drugs raise new issues about pricing? How might prices be determined and assessed? Will new drugs be affordable?
- How will society (governments) decide how to allocate resources to expensive new technologies? What are the ethical considerations?

Each panellist will be asked to speak for no more than 10 minutes, to be followed by a facilitated discussion and questions and answers from the floor.

- Moderator:
 - Robert G. Elgie, Chairperson, PMPRB
- Panellists:
 - Tim Caulfield, Health Law Institute, University of Alberta
 - Colleen Flood, Faculty of Law, University of Toronto
 - J. Mark Lievonon, President, Aventis Pasteur
 - Steve Morgan, Centre for Health Services and Policy Research, University of British Columbia
 - William J. Tholl, Secretary General and CEO, Canadian Medical Association

Registration

October 7 & 8, 2002

Fairmont Château Laurier, Ottawa, Ontario

First Name: _____ Last Name: _____

Title: _____

Organization: _____

Address: _____

City: _____ Province: _____

Country: _____ Postal Code: _____

Email: _____

Telephone: _____ Fax: _____

Special Requirements: (dietary, accessibility, other) _____

Space is limited – register early!!! Registration fees include all sessions, breakfasts, lunches and a reception. 175 seats available! In order to ensure the opportunity for all PMPRB stakeholders to be represented a differential registration fee structure has been established and it may be necessary to cap the participation of certain groups.

REGISTRATION FEES	Early Bird (until August 12, 2002)	Regular (after August 12, 2002)
-------------------	---------------------------------------	------------------------------------

Non-Profit Organization Delegate (consumer and patient advocacy groups)	\$425.00	\$475.00
---	----------	----------

Government Delegate and Academia	\$500.00	\$550.00
---	----------	----------

Other Delegates	\$850.00	\$950.00
------------------------	----------	----------

Symposium Registration Fee = \$ _____

Plus 7% GST (# 124063884RT) = \$ _____

Total Registration Fees to be paid = \$ _____

Method of Payment: Cheque made payable to "PMPRB/CEPMB Symposium 2002"
 VISA MASTERCARD AmEx

Name of Cardholder: _____

Signature of Cardholder: _____

Card Number: _____ Expiry Date: ____/____

Note: "Golden Planners Inc." will appear on your credit card statement.

Cancellations in writing will be accepted up to August 12, 2002, after which date no refunds will be issued. Replacements will be accepted up to September 27, 2002.

Hotel Accommodation

Fairmont Château Laurier
1 Rideau Street, Ottawa, ON

(\$199.00 single / double room plus applicable taxes / night)

All reservations must be made through Golden Planners Inc.

The hotel will not accept reservations directly but will issue a reservation confirmation. All reservations must be guaranteed with a credit card and must be received no later than **September 4, 2002** to reserve at the special conference rate.

Occupancy: Single Double / sharing with (name): _____

Room Type: Non-smoking Smoking

Arrival Date/Time: _____ Departure Date: _____

I authorize Golden Planners Inc. to use the above credit card to guarantee my hotel reservation,

or to use the following:

VISA MASTERCARD AmEx Account Number: _____

Name of Cardholder: _____ Expiry Date: ____/____

Signature of Cardholder: _____ Date: _____

Please complete and return the registration form with payment to:

PMPRB/CEPMB Symposium 2002, c/o Golden Planners Inc.
126 York Street, Suite 301, Ottawa, Ontario K1N 5T5

Tel: 613-241-9333 Fax: 613-565-2173 Email: info@goldenplanners.com

PmPrB
Symposium
2002